AI maps bowel cancer genetics to predict bevacizumab response
Researchers from the Institute of Cancer Research and RCSI used PhenMap, an AI tool, to analyze tumour genetics in 117 European advanced bowel cancer patients treated with bevacizumab, identifying patterns that predict non-response and potentially sparing thousands from ineffective treatment and side effects; the team plans to broaden testing and validate the approach for broader clinical use.